Mesoblast Limited (ASX: MSB) - ETF Exposure

Current share price for MSB : $2.460 0.05 (2.07%)⁺

Mesoblast Limited (MSB) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a Company that is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in reduction of the damaging inflammatory process.

MSB General Information ⁺

ASX Code	MSB
Website	http://www.mesoblast.com
Industry/Sector	Biotechnology
Market Cap ($M)	3,194
MSB Share Price	$2.460
Day High	$2.540
Day Low	$2.360
Last Close	$2.410
MSB Share Price Movement	$0.05 ( 2.07% )

Prices as at 16:40, 28 Aug 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to MSB

As a significant Australian company by market capitalisation, MSB is held across 20 ETFs spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when MSB moves, funds like ISO, SSO, FAIR, VSO and OZXX that hold it can move with it.

For more concentrated exposure, ETFs such as ISO (iShares S&P/ASX Small Ordinaries ETF Index Fund) allocate about 0.8% to MSB , while the average exposure across all 20 ETFs that hold it is around 0.2% .

Top ETF holdings

iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO) ~ 0.8%
SPDR S&P/ASX Small Ordinaries Fund (SSO) ~ 0.8%
BetaShares Australian Sustainability Leaders ETF (FAIR) ~ 0.5%
Vanguard MSCI Australian Small Companies Index ETF (VSO) ~ 0.3%
Global X Australia ex Financials & Resources ETF (OZXX) ~ 0.3%

Last updated: ETF data and holdings as at 30 August 2026

Own MSB directly or through an ETF?

How does holding Mesoblast Limited (MSB) shares directly compare to ETFs that include it?

	MSB Direct	ISO ASX	SSO ASX	FAIR ASX	VSO ASX	OZXX ASX
Holdings	1 company	198 holdings	202 holdings	83 holdings	194 holdings	104 holdings
MSB Weight	100%	0.8%	0.8%	0.5%	0.3%	0.3%
Diversification	Single Stock	Broad	Broad	Broad	Broad	Broad
Annual Cost	Brokerage only	0.55% p.a.	0.5% p.a.	0.49% p.a.	0.3% p.a.	0.25% p.a.
Approx. Yield	0%	4.19%	8.93%	3.04%	4.63%	5.15%
Star Ratings	-

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not MSB's direct yield. Annual cost uses each ETF's MER.

MSB Exposure on $10,000 investment

How a $10,000 investment in Mesoblast Limited (MSB) one week ago compares with ETFs that hold it.

Security	Investment type	Current price	7-day price movement	Dollar change	Value today
Mesoblast Limited (MSB)	Direct share	$2.460	4.24%	+$424	$10,424
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO)	Equity - Australia Small/Mid Cap	$5.210	-0.57%	-$57	$9,943
SPDR S&P/ASX Small Ordinaries Fund (SSO)	Equity - Australia Small/Mid Cap	$15.020	-0.53%	-$53	$9,947
BetaShares Australian Sustainability Leaders ETF (FAIR)	Equity - Australia Strategy	$19.000	-0.26%	-$26	$9,974
Vanguard MSCI Australian Small Companies Index ETF (VSO)	Equity - Australia Small/Mid Cap	$75.510	0.25%	+$25	$10,025
Global X Australia ex Financials & Resources ETF (OZXX)	Equity - Australia Sectors	$10.010	0.10%	+$10	$10,010

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Mesoblast Limited (MSB) ETFs

20 ETFs hold Mesoblast Limited (MSB).

ETF	MSB Weight	MER	Yield
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO)	0.8%	0.55%	4.19%
SPDR S&P/ASX Small Ordinaries Fund (SSO)	0.8%	0.5%	8.93%
BetaShares Australian Sustainability Leaders ETF (FAIR)	0.5%	0.49%	3.04%
Vanguard MSCI Australian Small Companies Index ETF (VSO)	0.3%	0.3%	4.63%
Global X Australia ex Financials & Resources ETF (OZXX)	0.3%	0.25%	5.15%
Betashares Australian Ex-20 Portfolio Diversifier ETF (EX20)	0.2%	0.2%	2.69%
Betashares Geared Australian Equity Fund (GEAR)	0.2%	2.11%	1.71%
Dimensional Australian Core Equity (Managed Fund) (DACE)	0.2%	0.28%	2.93%
iShares Core S&P/ASX 200 ETF (IOZ)	0.1%	0.05%	3.31%
Vanguard Ethically Conscious Australian Shares ETF (VETH)	0.1%	0.16%	2.8%

View all 20 ETFs

Mesoblast Limited (MSB) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Mesoblast Limited (MSB) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Mesoblast Limited (MSB) price-sensitive announcements

MSB - Major Milestone Treatment Completed in P3 Trial for CLBP

Mesoblast Limited has announced the completion of patient treatment in its pivotal Phase 3

Mesoblast Limited (MSB)
17 Aug 2026 | 10:00 AM

MSB - Quarterly Activities/Appendix 4C Cash Flow Report

The Quarterly Activities Report and Appendix 4C Cash Flow Report for Mesoblast Limited (AS

Mesoblast Limited (MSB)
30 Jul 2026 | 10:01 AM

MSB - Pivotal Phase 3 Trial in CLBP Achieves 300 Treated Patients

Mesoblast Limited announced the completion of their target of treating 300 patients in the

Mesoblast Limited (MSB)
14 Jul 2026 | 10:00 AM

MSB - Ryoncil Q4 Net Revenue of US$36M and US$115M for Full Year

Mesoblast Limited announced that their product, Ryoncil® (remestemcel-L-rknd), achieved a

Mesoblast Limited (MSB)
10 Jul 2026 | 9:57 AM

Mesoblast Limited (MSB) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Mesoblast Limited (MSB) ORDINARY FULLY PAID	Health Care	$3,195	MSB Annual Financial Results and Operational Update	27 Aug 2026 8:39AM	$2.360	$2.460	risen by 4.24%
Mesoblast Limited (MSB) ORDINARY FULLY PAID	Health Care	$3,195	Annual Financial Results Presentation	27 Aug 2026 8:33AM	$2.360	$2.460	risen by 4.24%
Mesoblast Limited (MSB) ORDINARY FULLY PAID	Health Care	$3,195	Preliminary Final Report including Appendix 4E	27 Aug 2026 8:21AM	$2.360	$2.460	risen by 4.24%
Mesoblast Limited (MSB) ORDINARY FULLY PAID	Health Care	$3,195	Appendix 3Y - Philip Krause	24 Aug 2026 5:50PM	$2.350	$2.460	risen by 4.68%
Mesoblast Limited (MSB) ORDINARY FULLY PAID	Health Care	$3,195	Notification regarding unquoted securities - MSB	24 Aug 2026 5:40PM	$2.350	$2.460	risen by 4.68%
Mesoblast Limited (MSB) ORDINARY FULLY PAID	Health Care	$3,195	Mesoblast 2026 Full Year Financial Results Webcast	24 Aug 2026 5:38PM	$2.350	$2.460	risen by 4.68%

MSB Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2028F	C2	-$4.40	-22.50%	0.00%	0.0%
2027F	C2	-$5.70	-18.50%	0.00%	0.0%
2026A	-$89.77	-$6.90	-43.80%	0.00%	0.0%

MSB Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F
CSL Limited (CSL)	$83,273M	0.7309	-0.4384	0.0505	10.7722	19.1821	18.2601	2.44%	2.42%	2.50%
Clinuvel Pharmaceuticals Limited (CUV)	$463M	0.0287	0.0000	0.0000	12.7855	0.0000	0.0000	0.54%	0.00%	0.00%
Immutep Limited (IMM)	$74M	0.1854	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Mesoblast Limited (MSB)	$3,130M	-0.4380	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$5,294M	-1.3893	0.0000	-0.9100	0.0000	147.5379	1,640.0000	0.00%	0.00%	0.00%

MSB Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	3.85	0.00
Market	0.64	17.10	1.67	1.32
Sector	0.64	31.20	2.63	2.65

MSB Directors

Name	Position	Start Date
Professor Silviu Itescu	Chief Executive Officer, Executive Director	8 Jun 2004
Dr Eric A Rose	Executive Director	15 Apr 2013
Ms Jane Catherine Bell	Non-Executive Director	18 Aug 2022
Dr Philip R Krause	Non-Executive Director	24 Mar 2022
Ms Lynette Elizabeth Cobley	Non-Executive Director	29 Apr 2025
Dr Gregory George	Non-Executive Director	24 Feb 2025
Mr Philip J. Facchina	Non-Executive Director, Non-Executive Chairman	29 Mar 2021
Mr William (Bill) A Burns	Non-Executive Director, Vice-Chairman	6 Mar 2014

Mesoblast Limited (MSB) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
17 Jul 2026	ITESCU, Silviu	Exercise	Options	1,885,334	$1.450	$2,733,734.000
17 Jul 2026	ITESCU, Silviu	Buy	Direct Shares	1,885,334	$1.450	$2,733,734.000
10 Apr 2026	GEORGE, Gregory	Buy	Indirect Shares	7,210,962	$1.445	$10,418,591.090

See all changes in directors' interest & trades for Mesoblast Limited (MSB) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

MSB Management

Name	Position
Eric Rose	Chief Medical Officer
Andrew Chaponnel	Chief Financial Officer
Peter Howard	Group General Counsel and Corporate Executive
Justin Horst	Head of Manufacturing
Geraldine Storton	Head of Regulatory Affairs and Quality Management
Fiona See	Head of Translational Research
Niva Sivakumar	Joint Company Secretary
Paul Hughes	Joint Company Secretary
Michael Schuster	Pharma Partnering
Paul Simmons	Scientific Advisor to the Chief Executive Officer

MSB Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Mesoblast Limited (MSB). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
267,021,132 (20.86%)	Gregory George Patching
78,958,928 (6.16%)	Silviu Itescu
64,171,900 (5.01%)	William Gueck

MSB Calendar of Events

Date	Event
26 August 2027	Report (Prelim)
26 February 2027	Report (Interim)
26 October 2026	Report (Annual)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us